CN106138079B - A kind of liniment and preparation method thereof for treating animal body surface parasitic disease - Google Patents
A kind of liniment and preparation method thereof for treating animal body surface parasitic disease Download PDFInfo
- Publication number
- CN106138079B CN106138079B CN201610610639.0A CN201610610639A CN106138079B CN 106138079 B CN106138079 B CN 106138079B CN 201610610639 A CN201610610639 A CN 201610610639A CN 106138079 B CN106138079 B CN 106138079B
- Authority
- CN
- China
- Prior art keywords
- liniment
- body surface
- animal body
- parasitic disease
- deionized water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000865 liniment Substances 0.000 title claims abstract description 48
- 241001465754 Metazoa Species 0.000 title claims abstract description 39
- 229940040145 liniment Drugs 0.000 title claims abstract description 36
- 208000030852 Parasitic disease Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000002480 mineral oil Substances 0.000 claims abstract description 19
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 19
- 239000008367 deionised water Substances 0.000 claims abstract description 18
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 18
- AGIQIKMGJVLKMA-NLRWUALESA-N (3ar,4as,5s,5ar,6ar)-5a-methyl-3-methylidene-5-(3-oxobutyl)-3a,4,4a,5,6,6a-hexahydrocyclopropa[f][1]benzofuran-2-one Chemical compound C1[C@@H]2C(=C)C(=O)O[C@@H]2C[C@]2(C)[C@@H](CCC(=O)C)[C@@H]21 AGIQIKMGJVLKMA-NLRWUALESA-N 0.000 claims abstract description 17
- AGIQIKMGJVLKMA-UHFFFAOYSA-N carabrone Natural products C1C2C(=C)C(=O)OC2CC2(C)C(CCC(=O)C)C21 AGIQIKMGJVLKMA-UHFFFAOYSA-N 0.000 claims abstract description 17
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims abstract description 15
- 239000005660 Abamectin Substances 0.000 claims abstract description 15
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 claims abstract description 15
- 229960002418 ivermectin Drugs 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 8
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 7
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004411 aluminium Substances 0.000 claims abstract description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000008117 stearic acid Substances 0.000 claims abstract description 7
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 14
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 7
- 229940063655 aluminum stearate Drugs 0.000 claims description 7
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- -1 lactone ketone Chemical class 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 28
- 229940079593 drug Drugs 0.000 description 25
- 238000012360 testing method Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 244000045947 parasite Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 206010021703 Indifference Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
A kind of liniment for treating animal body surface parasitic disease, the weight group per 100ml liniments become：0.1~3.0g of Carabrone, ivermectin or avermectin or 0.1~1.0g of doractin, 5.0~10.0g of absolute ethyl alcohol, 0~5.0g of polysorbate40,5.0~15.0g of deionized water, 5.0~10.0g of sorbester p18,3.0~10.0g of ethyl acetate, stearic acid 0.5~3.0g of aluminium powder, surplus are mineral oil.The present invention further discloses preparation method simultaneously.The present invention liniment is not only pest-resistant but also antibacterial, it is significant in efficacy；Its preparation process operability is strong, utilizes conversion.
Description
Technical field
The invention belongs to veterinary medicine technical fields, and in particular to a kind of liniment that treating animal body surface parasitic disease and its
Preparation method.
Background technology
Animal body surface parasitic disease refers to that can colonize in the parasite of animal body surface to be multiplied in animal body surface skin, given birth to
It deposits, causes skin surface tissue damage, the clinic table such as the pathological changes such as redness, rash block, incrustation occur, and show itch, pain
A kind of existing illness.The animal body surface parasite of most animals group is acarid, louse and flea.Particularly with non-intensive management
Livestock and poultry animal, due to manage it is not in place, expelling parasite is not in time, it is easier to lead to the occurrence of this disease.In addition, breeding environment humidity mistake
Greatly, it is this pathogenetic inducement that cleaning up excrement frequency is low, animal feeding density is big etc..
It is the most multiple with acarid disease in animal body surface parasitic disease, the various ages, kind animal can infect.It propagates
Mode be mainly by veterinary and healthy animal be in direct contact or by by acarid and its colony house of ovum pollution, pad grass and
Feeding management apparatus mediate contact etc..In addition, animal house is dark, moist, environment is unhygienic and malnutritive etc. can promote this
The occurrence and development of disease.Autumn and winter, especially rainy weather, disease sprawling are most fast.Although general epizoon will not prestige
The life of animal is coerced, but due to animal skin itch, local hemorrhage incrustation, other pathogenic bacteria of easy secondary infection.If passed
Dye diffusion, then can cause whole livestock and poultry feed intake to decline, and production performance reduces, and feedstuff-meat ratio increases, and economic benefit reduces.
Currently, the drug of commercially available current therapies animal body surface parasite is all water formulation.This preparation also plays centainly
Therapeutic effect, effect is ideal.But since these dosage forms overwhelming majority is water constituent or foreign minister is water.After being applied to skin, hold
It easily volatilizes, volatilizes rear active ingredient and crystallize out, effect is had a greatly reduced quality.Meanwhile in order to ensure effect, it is necessary to frequently repeatedly to skin
It is smeared in skin affected part.If it is people or pet, this way can meet substantially, easy to operate because quantity is few.But for facing
The livestock and poultry animal of bed cultivation, quantity is very huge, moreover domestic animal allows owner at will to smear unlike obedient pet, they can be anti-
It is anti-, result in that medication is time-consuming and laborious in this way, while to animal be also it is a kind of it is strong stress, be unfavorable for growth.
Invention content
The liniment of animal body surface parasitic disease is treated the purpose of the present invention is to provide a kind of, while preparation method being provided
It is another goal of the invention of the present invention.
Based on above-mentioned purpose, the present invention adopts the following technical scheme that：A kind of liniment for treating animal body surface parasitic disease, often
The weight group of 100ml liniments becomes：0.1~3.0g of Carabrone, ivermectin or avermectin or doractin 0.1~
1.0g, 5.0~10.0g of absolute ethyl alcohol, 0~5.0g of Tween-40,5.0~15.0g of deionized water, Arlacel-60 5.0~
10.0g, 3.0~10.0g of ethyl acetate, stearic acid 0.5~3.0g of aluminium powder, surplus is mineral oil.
Preferably, become per the weight group of 100ml liniments：0.5~2.0g of Carabrone, ivermectin or Avermectin
Element or 0.2~0.5g of doractin, 7.0~8.0g of absolute ethyl alcohol, Tween-40 0~3.0,5.0~10.0g of deionized water, department
7.0~the 9.0g of disk -60,5.0~8.0g of ethyl acetate, 1.0~2.0g of aluminum stearate, surplus are mineral oil.
It is further preferred that becoming per the weight group of 100ml liniments：Carabrone 1.0g, ivermectin 0.3g, nothing
Water-ethanol 8.0g, Tween-40 2.0g, deionized water 8.0g, Arlacel-60 8.0g, ethyl acetate 7.0g, aluminum stearate 1.5g,
Surplus is mineral oil.
The mineral oil is white oil or atoleine or the two mixture.
The deionized water is sterile deionized water.
The preparation method of the liniment of the treatment animal body surface parasitic disease, includes the following steps：（a）It will be in day name essence
Ester ketone, ivermectin or avermectin or doractin, absolute ethyl alcohol, ethyl acetate, Arlacel-60 are mixed to get system A；（b）
Tween-40 is add to deionized water, system B is obtained；（c）Stearic acid aluminium powder is added in mineral oil and is mixed, is heated to 120
~135 DEG C and 20~40min of maintenance, then -4 DEG C are cooled to hereinafter, obtaining system C；（d）System A, system B, system C are mixed, added
Enter in homogeneous emulsifying machine after emulsifying, constant volume, sealing packing to get.
Step（a）The concrete operations of middle system A are：First Carabrone is mixed with absolute ethyl alcohol；Again by Yi Wei bacterium
After element or avermectin or doractin are mixed with ethyl acetate, it is added in the mixed liquor of Carabrone and absolute ethyl alcohol
Continue to mix；Arlacel-60 is added later to mix up to system A.With direct mixed phase ratio, dissolved using drug when aforesaid operations
Time greatly shortens, and production efficiency significantly improves.
Usage and dosage：Usage, local topical are smeared.Dosage need to smear lesion according to skin focus position size
Entirely, ensure lesion all standing and smear uniform.Reasonable recipe of the present invention has specific aim to epizoon treatment, uses peace
Entirely；Clinical practice is curative for effect, small to Animal stress, twice medication, is spaced one week, you can reach promising result.
In prescription of the present invention, the effect that each component plays wherein is：
1）The absolute ethyl alcohol of selection is as solvent, other than absolute ethyl alcohol is safe to use, solubility is high, to medicine of the present invention
Liquid also has certain anti-corrosion effect, and may also function as convergence, Disinfection Effect after smearing in liniment of the present invention；
2）Selection ethyl acetate dissolving ivermectin or avermectin or doractin, the effect reached are：Acetic acid second
Ester is high to the solubility of drug, and pro-skin effect is good, and can bring drug into body surface after local skin is smeared in liniment of the present invention posts
In " the sore hole " of infested parasitism, by drug slow release, and high concentration is filled, and permanent action is played the role of；
3）Use mineral oil for final system foreign minister, the effect reached is：Mineral oil is petroleum fractionating extract, is not easy
Degradation, rotten, corruption, strong inert, and to drug substance stable of the present invention；Mineral oil can be in lesion after liniment partial smearing of the present invention
Place forms one layer of oil reservoir, which can prevent affected area moisture content from distributing chap, utilize rehabilitation；After medication simultaneously, oil reservoir can
Lesion surface is covered without dead angle, by air exclusion, so that a large amount of parasite in the inside is in anaerobic environment, makes its death by suffocation,
The course for the treatment of is substantially reduced, and will not be recurred, this is also an innovative point of the prescription of the present invention；
4）In the present invention, inventor confirms through many experiments, it is found that Tween-40 and Arlacel-60 are used cooperatively when ratio tween-
80 and Arlacel-80 stable system when being used cooperatively, and be also not in medicine layering in cryogenic conditions or the larger extraneous temperature difference
Wild effect；
Other than prescription advantage, of the invention is simple for process, need not introduce complicated equipment, general veterinary drug enterprises
The workshops GMP can produce, therefore production cost is low, be conducive to a wide range of popularization of drug.
Therefore, compared with prior art, by the improvement of prescription and technique, the technique effect reached is the present invention：First,
The present invention liniment is not only pest-resistant but also antibacterial, it is significant in efficacy, and be that water is different from foreign minister in the prior art, including the water of this liniment
Portion is not easy to volatilize, and drug is easy to immerse skin, and cutin-softening promotes curative effect；Secondly, which is reduced, and is reduced dynamic
Object stress, it is time saving and energy saving, reduce human cost, and property stablize, withstand high/low temperature and transport test, it is cost-effective, be conducive to
It promotes；Furthermore preparation process operability of the invention is strong, utilizes conversion.
Description of the drawings
Fig. 1 is the appearance material object photo of liniment of the present invention；
Fig. 2 is to confirm that liniment of the present invention meets the immiscible photo in kind of water；
Fig. 3 is to confirm that liniment density of the present invention is less than the photo in kind of water；
Fig. 4 be when Tween-80 and Arlacel-80 are used cooperatively under 40 DEG C of constant temperature, 70% relative humidities accelerated test
Design sketch（It places 1 month）；
Fig. 5 be when Tween-80 and Arlacel-80 are used cooperatively under 40 DEG C of constant temperature, 70% relative humidities accelerated test
Design sketch（It places 3 months）.
Specific implementation mode
The present invention will be illustrated by embodiment below, but these specific embodiments do not limit this hair in any way
Bright protection domain.
Embodiment 1-11
To keep specification succinct, the treatment animal body surface parasitic disease described in embodiment 1-11 is provided in the form of a table below
Liniment weight composition, be specifically shown in Table 1.
Weight composition in 1 embodiment 1-11 of table per 100ml liniments
。
The preparation method of the liniment for the treatment of animal body surface parasitic disease described in embodiment 1-11, includes the following steps：
（a）First Carabrone is mixed with absolute ethyl alcohol；Again by ivermectin or avermectin or doractin with
After ethyl acetate mixing, it is added to Carabrone and continues to mix with the mixed liquor of absolute ethyl alcohol；Sapn-is added later
60 mix up to system A；
（b）Tween-40 is add to deionized water, system B is obtained；
（c）Stearic acid aluminium powder is added in mineral oil and is mixed, be heated to 120~135 DEG C and maintains 20~40min, then
- 4 DEG C are cooled to hereinafter, obtaining system C；
（d）System A, system B, system C are mixed, are added in homogeneous emulsifying machine after emulsifying, constant volume, sealing packing,
To obtain the final product.
Embodiment 12
Difference from Example 1 is that the weight group per 100ml liniments becomes：Carabrone 0.1g, Avermectin
Element or doractin 0.1g, absolute ethyl alcohol 10.0g, Tween-40 5.0g, deionized water 5.0g, Arlacel-60 5.0g, acetic acid second
Ester 3.0g, stearic acid aluminium powder 0.5g, surplus is mineral oil.Remaining is the same as embodiment 1.
Embodiment 13
Difference from Example 1 is that the weight group per 100ml liniments becomes：Carabrone 3.0g, Avermectin
Element or doractin 1.0g, absolute ethyl alcohol 5.0g, Tween-40 3.0g, deionized water 15.0g, Arlacel-60 10.0g, acetic acid second
Ester 10.0g, stearic acid aluminium powder 3.0g, surplus is mineral oil.Remaining is the same as embodiment 1.
Embodiment 14
Difference from Example 1 is that the weight group per 100ml liniments becomes：Carabrone 0.5g, Avermectin
Element or doractin 0.2g, absolute ethyl alcohol 8.0g, Tween-40 3.0, deionized water 10.0g, Arlacel-60 7.0g, ethyl acetate
5.0g, aluminum stearate 1.0g, surplus are mineral oil.Remaining is the same as embodiment 1.
Embodiment 15
Difference from Example 1 is that the weight group per 100ml liniments becomes：Carabrone 2.0g, Avermectin
Element or doractin 0.5g, absolute ethyl alcohol 7.0g, Tween-40 1.0, deionized water 5.0g, Arlacel-60 9.0g, ethyl acetate
8.0g, aluminum stearate 2.0g, surplus are mineral oil.Remaining is the same as embodiment 1.
Test example 1-3
The product property and stability experiment of 1 product of the present invention of test example
The product that the present invention obtains is the uniform milky white liquid of quality, and appearance material object photo is as shown in Figure 1；Scheme simultaneously
2 confirm that the liniment chance water of the present invention is immiscible；Fig. 3 is then to confirm that liniment density of the present invention is less than water.
The embodiment of the present invention 1-15 is sampled, room temperature, 40 DEG C of high temperature height are respectively carried out to each embodiment
Wet placement, 4 DEG C of low temperature are placed and -20 DEG C of freezings are placed, and separately sampled observation character when 0d, 15d, 30d, 90d and 180d,
As a result, it has been found that situation is precipitated without layering and drug in the product that each embodiment obtains, there is preferable stability.
Meanwhile in order to prove that effect that Tween-40 and Arlacel-60 are used cooperatively, inventor use Tween-80 and sapn-
80 with the use of being compared, and Fig. 4 and Fig. 5 give when Tween-80 and Arlacel-80 are used cooperatively in 40 DEG C of constant temperature, 70% phase
To the design sketch of accelerated test under damp condition, Fig. 4 is after placing 1 month, it can be seen that there is the wild effect being layered in drug,
Fig. 5 is after placing 3 months, and drug is outer in addition to there is layering, and upper layer color begins to change into light brown, and has brown solid substance to analyse
The wild effect gone out.
2 safety experiment of test example
The safety used below by way of clinical trial verification drug.
The Kun Ming mice 30 for choosing 20g or so after abdomen is lost hair or feathers with depilatory agent, divides 3 groups, every group 10.First
Group is control group, smears physiological saline processing, and second group is 1 group of experiment, and skin has taken off scrapes " # " after hair with pocket knife, to ooze slightly
Blood is degree, then smears the liniment of the present invention（Embodiment 1 is prepared）；Third group is 2 groups of experiment, this hair is directly smeared after depilation
Bright liniment（Embodiment 1 is prepared）, be observed continuously one week after smearing, and record the drinking-water of each group mouse, diet, death,
The local skin feature of clinical manifestation and coating.
Experimental result：
1. each group mouse drinking-water, diet are all normal, indifference；
2. each group mouse does not occur death；
3. each group mouse is without poisoning clinical manifestation；
4. the coating position of three groups of mouse does not occur the pathological signs such as redness, pain, local circulation obstacle；
The result shows that：The liniment of the present invention is safe to use to healthy skin and damaged skin, will not cause dead drawn game
Portion's inflammatory reaction.
3 test of pesticide effectiveness of test example
Somewhere morbidity pig farm, the growing and fattening pigs of 4 monthly ages, since breeding environment is poor, along with ambient humidity is big, cleaning up excrement frequency
It is low, jumpbogroup pig body surface occur bronzing spot, protrusion of surface lesion, lesion is scraped into partial necrosis skin with pocket knife（Disease is strong
Intersection）Microscope inspection, it can be seen that have the presence of acarid polypide, it is possible thereby to judge that erythema lesion is caused by acarid.Disease
Animal body surface is become thin, and hair coke the part between the ribs and the hips is hung, and is itched due to skin and is often rubbed against wall, and chafing is serious, and skin depth is coarse, and part is de-
Hair, affected area have crust more.Sick pig is divided to blank not medication group, common Ivermectin Lotion group and liniment group of the present invention at random
（For being made by embodiment 1）It three groups, every group 20, separately raises in same environment, by common Ivermectin Lotion and Ben Fa
Bright liniment is applied to the porcine skin affected area of experiment medication group, and the first day once smears, and medication is smeared again after 7 days, it is ensured that smears
Uniformly, duration of trial is 10 days, during experiment by pig cultivation in the environment of dried sanitary, in order to avoid environment superinfection.Medication
It observes pig behavior and affected area recovery situation daily afterwards, and records, the results are shown in Table shown in 2.
Evaluation criterion：
It is dead：Test pig occurs dead during finger to finger test, -1 point；
In vain：After referring to medication, though test pig does not occur death, Symptoms and sign do not have improvement sign, 0 point；
It lapses to：Refer to medication after, test pig achieves certain effect, be in convalescence, 1 point；
Recovery from illness：Refer to medication after, test pig fully recovers, with before the onset all behaviors and sign indifference, 2 points；
Total effective rate：Ratio × 100% of the test pig number and this group of test pig sum that lapse to and fully recover after referring to medication；
Protective rate：Refer to the total effective rate that the total effective rate after medication subtracts the control group of non-medication；
Table 2 is using liniment of the present invention and the comparative efficacy test for not using liniment of the present invention
。
Test result：Control group does not have to any drug, in the case of leaning on animal itself resistance completely, lapses to rate 10%, fullys recover from an illness
More rate 0%, total effective rate 10%；Common Ivermectin Lotion group, lapses to rate 40%, cure rate 35%, total effective rate 75%, this hair
Bright group after the treatment epizoon liniment using the present invention, lapses to rate 20%, cure rate 75%, total effective rate 95%, hence it is evident that
Better than other two groups, 85% is reached to the protective rate of infected animal.
Conclusion (of pressure testing)：Treatment of the liniment to animal body surface parasite for treating animal body surface parasitic disease of the present invention
With notable curative effect.
Claims (7)
1. a kind of liniment for treating animal body surface parasitic disease, which is characterized in that the weight group per 100ml liniments becomes：Its name
0.1~3.0g of smart lactone ketone, ivermectin or avermectin or doractin 0.1~1.0g, 5.0~10.0g of absolute ethyl alcohol are spat
Temperature -40 0~5.0g, 5.0~15.0g of deionized water, 5.0~10.0g of Arlacel-60,3.0~10.0g of ethyl acetate, stearic acid
0.5~3.0g of aluminium powder, surplus are mineral oil.
2. the liniment for the treatment of animal body surface parasitic disease as described in claim 1, which is characterized in that per the weight of 100ml liniments
Amount group becomes：0.5~2.0g of Carabrone, ivermectin or avermectin or 0.2~0.5g of doractin, absolute ethyl alcohol
7.0~8.0g, 0~3.0g of Tween-40,5.0~10.0g of deionized water, 7.0~9.0g of Arlacel-60, ethyl acetate 5.0~
8.0g, 1.0~2.0g of aluminum stearate, surplus are mineral oil.
3. the liniment for the treatment of animal body surface parasitic disease as claimed in claim 2, which is characterized in that per the weight of 100ml liniments
Amount group becomes：Carabrone 1.0g, ivermectin 0.3g, absolute ethyl alcohol 8.0g, Tween-40 2.0g, deionized water
8.0g, Arlacel-60 8.0g, ethyl acetate 7.0g, aluminum stearate 1.5g, surplus are mineral oil.
4. the liniment of the treatment animal body surface parasitic disease as described in claims 1 or 2 or 3, which is characterized in that the mineral oil
For atoleine.
5. the liniment for the treatment of animal body surface parasitic disease as claimed in claim 4, which is characterized in that the deionized water is to go out
Bacterium deionized water.
6. the preparation method of the liniment of the treatment animal body surface parasitic disease described in claims 1 or 2 or 3 or 5, feature exist
In including the following steps：（a）By Carabrone, ivermectin or avermectin or doractin, absolute ethyl alcohol, acetic acid
Ethyl ester, Arlacel-60 are mixed to get system A；（b）Tween-40 is add to deionized water, system B is obtained；（c）By aluminum stearate
Powder is added in mineral oil and mixes, and is heated to 120~135 DEG C and maintains 20~40min, then is cooled to -4 DEG C hereinafter, the system of obtaining
C；（d）System A, system B, system C are mixed, are added in homogeneous emulsifying machine after emulsifying, constant volume, sealing packing to get.
7. the preparation method of the liniment for the treatment of animal body surface parasitic disease as claimed in claim 6, which is characterized in that step
（a）The concrete operations of middle system A are：First Carabrone is mixed with absolute ethyl alcohol；Again by ivermectin or avermectin
Or after doractin is mixed with ethyl acetate, it is added to Carabrone and continues to mix with the mixed liquor of absolute ethyl alcohol；It
After add Arlacel-60 and mix up to system A.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610610639.0A CN106138079B (en) | 2016-07-29 | 2016-07-29 | A kind of liniment and preparation method thereof for treating animal body surface parasitic disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610610639.0A CN106138079B (en) | 2016-07-29 | 2016-07-29 | A kind of liniment and preparation method thereof for treating animal body surface parasitic disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106138079A CN106138079A (en) | 2016-11-23 |
| CN106138079B true CN106138079B (en) | 2018-08-24 |
Family
ID=57327658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610610639.0A Expired - Fee Related CN106138079B (en) | 2016-07-29 | 2016-07-29 | A kind of liniment and preparation method thereof for treating animal body surface parasitic disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138079B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952372A (en) * | 1998-09-17 | 1999-09-14 | Mcdaniel; William Robert | Method for treating rosacea using oral or topical ivermectin |
| CN101623256A (en) * | 2008-07-08 | 2010-01-13 | 中国农业科学院兰州畜牧与兽药研究所 | Ivermectin nanoemulsion drug combination and preparation method thereof |
| CN103788037A (en) * | 2012-11-02 | 2014-05-14 | 西北农林科技大学 | Method for purifying carabrone |
| CN105616500A (en) * | 2016-01-20 | 2016-06-01 | 吕欢 | Pharmaceutical composition for treating cestodiasis and preparation method thereof |
-
2016
- 2016-07-29 CN CN201610610639.0A patent/CN106138079B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952372A (en) * | 1998-09-17 | 1999-09-14 | Mcdaniel; William Robert | Method for treating rosacea using oral or topical ivermectin |
| CN101623256A (en) * | 2008-07-08 | 2010-01-13 | 中国农业科学院兰州畜牧与兽药研究所 | Ivermectin nanoemulsion drug combination and preparation method thereof |
| CN103788037A (en) * | 2012-11-02 | 2014-05-14 | 西北农林科技大学 | Method for purifying carabrone |
| CN105616500A (en) * | 2016-01-20 | 2016-06-01 | 吕欢 | Pharmaceutical composition for treating cestodiasis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106138079A (en) | 2016-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2222563C (en) | Pharmaceutical compositions, based on etheric oils obtained from plants for use in the human and veterinary medical field | |
| Yildiz et al. | An evaluation of soybean lecithin as an alternative to avian egg yolk in the cryopreservation of fish sperm | |
| CN103621470A (en) | Disease-free cultivation technology, namely comprehensive swine disease prevention and treatment measure | |
| Feng et al. | Evaluation of the burn healing properties of oil extraction from housefly larva in mice | |
| CN103961283B (en) | A kind of anti-acne repairs lyophilized formulations and preparation and application thereof | |
| Mylonas et al. | Enhancement of oogenesis/spermatogenesis in meagre Argyrosomus regius using a combination of temperature control and GnRHa treatments | |
| CN102416023A (en) | Periplaneta Americana L. and gel externally applied medicinal composition and preparation method and use thereof in preparation of externally applied medicines for treating scalding | |
| CN104306358A (en) | Itching-relieving scar-removing coating agent | |
| Börkü et al. | Ivermectin is an effective treatment for bovine cutaneous papillomatosis | |
| Riet-Correa et al. | Spontaneous acute poisoning by Crotalaria retusa in sheep and biological control of this plant with sheep | |
| CN106511267A (en) | Compound moxidectin drops as well as preparation method and application thereof | |
| CN102600195A (en) | Composite transdermal linimentum for pets as well as preparation method and application of composite transdermal linimentum | |
| CN106138079B (en) | A kind of liniment and preparation method thereof for treating animal body surface parasitic disease | |
| CN107582943A (en) | A kind of herbal mixture transdermal spray agent for preventing and treating animal psoroptic mange and preparation method | |
| Visser et al. | The treatment of bovine sarcoptic mange (Sarcoptes scabiei var. bovis) using eprinomectin extended-release injection | |
| CN102986696A (en) | Acaricidal composition containing fluacrypyrim and bifenazate | |
| Marsella et al. | Use of pentoxifylline in the treatment of allergic contact reactions to plants of the Commelinceae family in dogs | |
| CN105963243A (en) | Borneol camphor essential oil slow-release cream for curing acne vulgaris and preparation method thereof | |
| Islam et al. | Clinicopathological studies on gentamicin toxicity in White Leghorn commercial layers | |
| JP2019178170A (en) | Use of patchouli extract in preparation of compositions with anti-microorganism effect | |
| CN109833296A (en) | Can the new merit chigger disease of prevention and control plants essential oil microemulsion formulation and preparation method thereof | |
| CN115192642A (en) | Preparation method and application of composite biological preparation with parasite killing function and containing brevibacillus laterosporus and fermented traditional Chinese medicine | |
| CN104225583B (en) | A kind of compositions repaired for skin injury | |
| RU2563358C1 (en) | Method of improvement of reproductive function of cows and vitality of new-born calves | |
| Kotb et al. | Epidemiological studies of equine mange with special reference to different therapeutic protocols for effective treatment of Chorioptic mange |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180824 |